Age-specific survival in acute myeloid leukemia in the Nordic countries through a half century

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11140%2F24%3A10478592" target="_blank" >RIV/00216208:11140/24:10478592 - isvavai.cz</a>
Result on the web
<a href="https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=pTGdrknLIO" target="_blank" >https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=pTGdrknLIO</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1038/s41408-024-01033-7" target="_blank" >10.1038/s41408-024-01033-7</a>

Result language
angličtina
Original language name
Age-specific survival in acute myeloid leukemia in the Nordic countries through a half century
Original language description
Overall survival has developed well in hematological malignancies but among the main entities, 5-year survival in acute myeloid leukemia (AML) has remained the lowest of all, mainly because of the poor survival of the old patients (half of patients are 70+ years at diagnosis). The improvements in AML survival were achieved through traditional intensive chemotherapy with cytosine arabinoside (ara-C) and anthracyclines, and these have remained the mainstay of intensive chemotherapy with curative intent.
Czech name
—
Czech description
—

Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30204 - Oncology

Project
<a href="/en/project/EH22_008%2F0004644" target="_blank" >EH22_008/0004644: Saving lives through research in early cancer detection and prevention: Molecular, genomic and societal factors</a><br>
Continuities
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Publication year
2024
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Similar results(10)